Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

Key reasons to become a member:

Meet new partners and end-users
Share your success stories
Benefit from unique advantages
Shape the future of Nanomedicine in europe
Promote and educate

Know more

ETPN strategic inputs

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Know more

ETPN support to innovation

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

Know more

Are you on the Nanomedicine map?

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.

See the map



Latest news

Public consultation about the Health PPP Strategic Research & Innovation Agenda is open!

Oct 23, 2019

Bring your contribution to shape the Health PPP!
Today is launched a public consultation on the Strategic Research Agenda (SRA) for the European Partnership for Health Innovation.
Deadline to answer the survey: November, 24, 2019.

Ruth Schmid is elected new Chairperson of the ETPN! Meet the new Executive Board.

Jun 21, 2019

Ruth Schmid , VP Marketing at SINTEF, has been elected new chairperson of the ETP Nanomedicine Executive Board during the General Assembly held on June 17th 2019 on the fist day of the Nanomed Europe 2019 event (NME19) in Braga, Portugal. She will lead the platform with the support of a brilliant and entirely renewed team, with notably Agnès Pottier (Head of Discovery at Nanobiotix) and Raymond Schiffelers (Professor in Nanomedicine at UMC Utrecht) as vice chairpersons.